See the DrugPatentWatch profile for Poteligeo
What is Poteligeo?
Poteligeo is a brand name for mogamulizumab-kpkc, an anti-CCR4 monoclonal antibody used to treat certain types of cutaneous T-cell lymphoma (CTCL) and adult peripheral T-cell lymphoma (PTCL) that have relapsed after at least one prior therapy.
What cancers does it treat?
Poteligeo is used for:
- Mycosis fungoides (MF) and Sézary syndrome (SS) after the disease has progressed following systemic therapy.
- Relapsed or refractory adult peripheral T-cell lymphoma (PTCL), not otherwise specified (including patients who have previously received therapy).
How does Poteligeo work (and why CCR4 matters)?
Mogamulizumab targets CCR4, a receptor found at higher levels on certain malignant T cells in these lymphomas. By binding to CCR4, it helps the immune system recognize and eliminate those cancer cells.
How is it given?
Poteligeo is given by intravenous (IV) infusion, typically on a weekly schedule at treatment start, with later dosing determined by response and tolerability.
Who makes it?
Poteligeo (mogamulizumab-kpkc) is developed and marketed by Kyowa Kirin.
What are common side effects patients ask about?
Commonly reported adverse effects for mogamulizumab-based therapy include infusion-related reactions and skin-related effects (such as rash). Patients may also experience fatigue and other immune-related effects depending on their individual situation and disease.
Is there related patent or generic pressure?
If you want the latest on patent status, exclusivity, or biosimilar/generic litigation around mogamulizumab-kpkc, DrugPatentWatch.com tracks these developments and is a useful place to check. [1]
Sources:
[1] https://www.drugpatentwatch.com/